New Patents Provide Additional Coverage for Lead Product Candidates FMX101, FMX102, and FDX104
Rehovot, Israel and Bridgewater, NJ – November 13, 2014 – Foamix Pharmaceuticals Ltd. (“Foamix Pharmaceuticals”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that the United States Patent and Trademark Office (“USPTO”) has recently issued to it two additional patents, namely U.S. Patent No. 8,865,139 and U.S. Patent No. 8,871,184, each entitled "Topical tetracycline compositions". Both patents are expectedtobe in effect until 2030.
These two new patents relate to compositions of matter comprising claims to a tetracycline antibiotic formulation and its physical properties. The tetracycline antibiotic includes minocycline and doxycycline, which are the subject of Foamix’s lead product candidates FMX101 and FMX102, comprising minocycline, and FDX104, comprising doxycycline. These patents also relate to methods of treatment of dermatological disorders, such as acne, impetigo and rosacea.
Foamix Pharmaceuticals currently has 73 granted patents and 114 patent applications worldwide. In the United States, Foamix has established a patent portfolio of 34 granted patents and 59 pending patent applications concerning our foam-based platforms and other technologies.
About Foamix Pharmaceuticals Ltd.
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix Pharmaceuticals’ lead product candidate, FMX101 for moderate-to-severe acne, is a novel topical foam formulation of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain "forward-looking statements" relating to future events. Forward-looking statements are based on Foamix Pharmaceuticals’ current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix Pharmaceuticals undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Acknowledgement: The development of Minocycline foam was aided by a loan from the BIRD Foundation: www.birdf.com